Retina Practice Working Capital: Funding Drug Costs
Retina practice working capital is the cash a retina group needs to keep operating while it waits to be paid. In most medical practices, the biggest expenses are payroll and rent. In retina, the cost of injectable drugs used to treat macular degeneration, diabetic eye disease and retinal vein occlusion can rival or exceed those costs, and the practice often pays for those drugs before it is reimbursed.
That timing gap can put pressure on even a well-run, profitable practice. This guide explains why retina practices face unusual cash flow demands and how financing may help. Reimbursement, drug acquisition and billing rules vary by payer and change over time, and nothing here is billing, coding, compliance or clinical advice.
Why Retina Practices Have Unusual Cash Needs
Many retina practices purchase injectable drugs, store them, administer them in the office and then bill payers. This is often called buy-and-bill. It creates several working capital pressures:
- Drug inventory: practices may hold significant drug inventory to keep clinics running
- Payment timing: distributor invoices may come due before claims are paid
- Thin drug margins: the difference between acquisition cost and reimbursement may be small or may change
- Patient cost sharing: some revenue depends on collecting balances from patients or secondary payers
- Prior authorizations and denials: delayed or denied claims can tie up cash for longer
As a practice grows and injection volume increases, its drug purchases grow too. Growth can therefore increase the need for working capital rather than reduce it.
Signs Your Retina Practice May Need More Working Capital
Cash flow strain does not always show up on the income statement. A practice can be profitable on paper while its bank balance is under pressure. Warning signs may include:
- Regularly timing drug orders around expected payer deposits
- Rising accounts receivable as injection volume grows
- Partners deferring distributions to cover operating costs
- Difficulty taking advantage of purchasing terms or volume programs
- Delaying equipment purchases or hiring because cash is tied up in drugs
Tracking metrics such as days in accounts receivable, denial rates and drug inventory levels can help owners see the problem earlier. Our article on key performance indicators for an ophthalmology practice covers metrics that may be useful to monitor.
Retina Practice Working Capital Options
Several financing tools can help a retina practice manage the gap between buying drugs and collecting payment.
Revolving Line of Credit
A revolving line of credit allows a practice to draw funds when drug invoices come due and repay the balance as claims are collected. Because retina cash needs rise and fall with purchasing and payment cycles, a line of credit is often a natural fit. Our article on the ophthalmology practice line of credit explains how these facilities are typically structured and reviewed.
Working Capital Term Loans
A term loan provides a lump sum repaid over a set period. It may help a practice build a permanent cash cushion, cover the cost of adding a new location or support a transition after an acquisition. Our working capital solutions page explains how term working capital can be structured.
Working Capital as Part of an Acquisition or Expansion
When a buyer acquires a retina practice or a group opens a satellite clinic, the financing package may include working capital alongside the purchase price or build-out. Planning for drug inventory from the start can help avoid a cash squeeze in the first months. Our guide on how to buy a retina practice covers this issue in more detail.
All options depend on the practice’s cash flow, existing debt, collateral and lender review, and every loan is subject to approval.
What Lenders Look for
Lenders reviewing a working capital request for a retina practice may look at:
- Historical revenue and cash flow, including drug and professional revenue
- Accounts receivable aging by payer
- Payer mix and exposure to Medicare and Medicare Advantage plans
- Drug purchasing patterns and distributor terms
- Existing debt, including equipment loans and leases
- The owners’ experience and financial strength
Lenders understand that drug revenue can make a retina practice look different from other specialties. Clear reporting that separates drug revenue from professional and ancillary revenue can help a lender understand the business.
Planning for Reimbursement Changes
Retina practices are heavily exposed to Medicare. Changes to the physician fee schedule, drug payment methodology or the adoption of new drugs and biosimilars can affect both margins and cash needs. Our article on ophthalmology Medicare cuts explains how reimbursement changes can affect a practice’s borrowing capacity.
Owners may want to review their working capital plan whenever there is a significant change in drug mix, payer contracts or injection volume. Qualified billing or compliance professionals can help evaluate reimbursement questions.
Practical Ways to Reduce Cash Strain
Financing is only part of the solution. Practices may also want to:
- Review prior authorization and claims workflows with qualified billing professionals
- Monitor drug inventory closely to avoid overstocking
- Track patient balances and collection processes
- Compare distributor payment terms and purchasing options
- Forecast cash needs before adding doctors, clinic days or locations
Final Thoughts
Retina practice working capital is not just a cushion for slow months. For many retina groups, it is a core part of how the business functions, because drug costs and payment timing create cash needs that grow with the practice. Planning ahead and choosing the right mix of credit can help owners focus on patient care rather than on timing invoices.
US Medical Funding helps retina specialists and ophthalmologists finance working capital, acquisitions and growth. Learn more about our ophthalmology practice working capital financing.
